protein tyrosine phosphatase receptor type RGenealiases: EC-PTP · PCPTP1 · PTP-SL · PTPBR7 · PTPRQ
Q-omics provides the consensus-scored PTPRR profile across patient tissues and cancer cell-line models. PTPRR expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PTPRR is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PTPRR RNA expression shows 15,724 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where PTPRR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRR survival associations across molecular data types. PTPRR RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRR RNA expression–survival associations across cancer types. High PTPRR expression shows unfavorable associations in MESO, HNSC, PAAD and LUSC, but favorable associations in BLCA and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PTPRR RNA expression.
This table summarizes PTPRR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PTPRR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRR shows lower tumor expression in LUSC, COAD and LUAD and higher tumor expression in HNSC, KIRC and BRCA. The HNSC box plot shows higher PTPRR RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with PTPRR in patient tissues and cancer cell lines. In patient samples, PTPRR shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
